Abstract
Lipid-lowering treatment with statins is effective for primary and secondary prevention
of coronary artery disease in patients with either hypercholesterolemia or average
cholesterol levels. Several clinical trials in progress will investigate the use of
statins in entirely elderly or diabetic cohorts, and larger trials will continue to
include significant numbers of these patients, as well as greater numbers of women.
Additional clinical endpoint trials are assessing the potential benefits of lowering
lipid levels to below currently recommended goals and of aggressive early statin treatment
to prevent ischemic events in patients with stable coronary disease or acute coronary
syndromes. These trials are expected to yield important data on the relation of lipid
reduction to the prevention of coronary artery disease and on the potential for extending
the use of statins.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).Circulation. 1994; 89: 1329-1345
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease.Lancet. 1994; 344: 1383-1389
- Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.N Engl J Med. 1995; 333: 1301-1307
- The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.N Engl J Med. 1996; 335: 1001-1009
- Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels.JAMA. 1998; 279: 1615-1622
- Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.N Engl J Med. 1998; 339: 1349-1357
- 2001 Heart and Stroke Statistical Update. American Heart Association, Dallas2000
- The design of a Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).Am J Cardiol. 1999; 84: 1192-1197
- MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death.Eur Heart J. 1999; 20: 725-741
- Management of dyslipidemia in adults with diabetes.Diabetes Care. 2000; 23: 557-565
- Diabetes and cardiovascular disease.JAMA. 1979; 241: 2035-2038
- The impact of diabetes on survival following myocardial infarction in men vs. women.JAMA. 1988; 260: 3456-3460
- Prevention of coronary heart disease in clinical practice.Eur Heart J. 1994; 15: 1300-1331
- Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM.Diabetes Care. 1998; 21: 477-481
- Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.Diabet Med. 1998; 14: 564-570
- The Women’s Ischemia Syndrome Evaluation (WISE) study.Crit Care Med. 1999; 27: 1787-1793
- Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).J Hypertens. 1996; 9: 342-360
- Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone.JAMA. 2000; 283: 1967-1975
- Executive Summary of the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).JAMA. 2001; 285: 2486-2497
- Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S).Circulation. 1998; 97: 1453-1460
- Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.Circulation. 1998; 97: 1446-1452
LaRosa JC, for the TNT Steering Committee. Effect of lowering LDL-C beyond currently recommended minimum targets: the Treating to New Targets (TNT) study. Abstract presented at the XIII International Symposium on Drugs Affecting Lipid Metabolism. Florence, Italy, May 30–June 3, 1998.
- Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease.Circulation. 1997; 95: 324-328
- Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S).J Am Coll Cardiol. 1998; 81: 333-335
- Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE).Am J Cardiol. 2000; 86: 250-252
Article info
Identification
Copyright
© 2001 Excerpta Medica Inc. Published by Elsevier Inc. All rights reserved.
